File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Encapsulation of Ibuprofen in CD-MOF and Related Bioavailability Studies

TitleEncapsulation of Ibuprofen in CD-MOF and Related Bioavailability Studies
Authors
Keywordscyclodextrin
drug delivery
ibuprofen
metal−organic framework
Issue Date2017
Citation
Molecular Pharmaceutics, 2017, v. 14, n. 5, p. 1831-1839 How to Cite?
AbstractAlthough ibuprofen is one of the most widely used nonsteroidal anti-inflammatory drugs (NSAIDs), it exhibits poor solubility in aqueous and physiological environments as a free acid. In order to improve its oral bioavailability and rate of uptake, extensive research into the development of new formulations of ibuprofen has been undertaken, including the use of excipients as well as ibuprofen salts, such as ibuprofen lysinate and ibuprofen, sodium salt. The ultimate goals of these studies are to reduce the time required for maximum uptake of ibuprofen, as this period of time is directly proportional to the rate of onset of analgesic/anti-inflammatory effects, and to increase the half-life of the drug within the body; that is, the duration of action of the effects of the drug. Herein, we present a pharmaceutical cocrystal of ibuprofen and the biocompatible metal-organic framework called CD-MOF. This metal-organic framework (MOF) is based upon γ-cyclodextrin (γ-CD) tori that are coordinated to alkali metal cations (e.g., K+ ions) on both their primary and secondary faces in an alternating manner to form a porous framework built up from (γ-CD)6 cubes. We show that ibuprofen can be incorporated within CD-MOF-1 either by (i) a crystallization process using the potassium salt of ibuprofen as the alkali cation source for production of the MOF or by (ii) absorption and deprotonation of the free-acid, leading to an uptake of 23-26 wt % of ibuprofen within the CD-MOF. In vitro viability studies revealed that the CD-MOF is inherently not affecting the viability of the cells with no IC50 value determined up to a concentration of 100 μM. Bioavailability investigations were conducted on mice, and the ibuprofen/CD-MOF pharmaceutical cocrystal was compared to control samples of the potassium salt of ibuprofen in the presence and absence of γ-CD. From these animal studies, we observed that the ibuprofen/CD-MOF-1 cocrystal exhibits the same rapid uptake of ibuprofen as the ibuprofen potassium salt control sample with a peak plasma concentration observed within 20 min, and the cocrystal has the added benefit of a 100% longer half-life in blood plasma samples and is intrinsically less hygroscopic than the pure salt form.
Persistent Identifierhttp://hdl.handle.net/10722/333635
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 0.940
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHartlieb, Karel J.-
dc.contributor.authorFerris, Daniel P.-
dc.contributor.authorHolcroft, James M.-
dc.contributor.authorKandela, Irawati-
dc.contributor.authorStern, Charlotte L.-
dc.contributor.authorNassar, Majed S.-
dc.contributor.authorBotros, Youssry Y.-
dc.contributor.authorStoddart, J. Fraser-
dc.date.accessioned2023-10-06T05:21:12Z-
dc.date.available2023-10-06T05:21:12Z-
dc.date.issued2017-
dc.identifier.citationMolecular Pharmaceutics, 2017, v. 14, n. 5, p. 1831-1839-
dc.identifier.issn1543-8384-
dc.identifier.urihttp://hdl.handle.net/10722/333635-
dc.description.abstractAlthough ibuprofen is one of the most widely used nonsteroidal anti-inflammatory drugs (NSAIDs), it exhibits poor solubility in aqueous and physiological environments as a free acid. In order to improve its oral bioavailability and rate of uptake, extensive research into the development of new formulations of ibuprofen has been undertaken, including the use of excipients as well as ibuprofen salts, such as ibuprofen lysinate and ibuprofen, sodium salt. The ultimate goals of these studies are to reduce the time required for maximum uptake of ibuprofen, as this period of time is directly proportional to the rate of onset of analgesic/anti-inflammatory effects, and to increase the half-life of the drug within the body; that is, the duration of action of the effects of the drug. Herein, we present a pharmaceutical cocrystal of ibuprofen and the biocompatible metal-organic framework called CD-MOF. This metal-organic framework (MOF) is based upon γ-cyclodextrin (γ-CD) tori that are coordinated to alkali metal cations (e.g., K+ ions) on both their primary and secondary faces in an alternating manner to form a porous framework built up from (γ-CD)6 cubes. We show that ibuprofen can be incorporated within CD-MOF-1 either by (i) a crystallization process using the potassium salt of ibuprofen as the alkali cation source for production of the MOF or by (ii) absorption and deprotonation of the free-acid, leading to an uptake of 23-26 wt % of ibuprofen within the CD-MOF. In vitro viability studies revealed that the CD-MOF is inherently not affecting the viability of the cells with no IC50 value determined up to a concentration of 100 μM. Bioavailability investigations were conducted on mice, and the ibuprofen/CD-MOF pharmaceutical cocrystal was compared to control samples of the potassium salt of ibuprofen in the presence and absence of γ-CD. From these animal studies, we observed that the ibuprofen/CD-MOF-1 cocrystal exhibits the same rapid uptake of ibuprofen as the ibuprofen potassium salt control sample with a peak plasma concentration observed within 20 min, and the cocrystal has the added benefit of a 100% longer half-life in blood plasma samples and is intrinsically less hygroscopic than the pure salt form.-
dc.languageeng-
dc.relation.ispartofMolecular Pharmaceutics-
dc.subjectcyclodextrin-
dc.subjectdrug delivery-
dc.subjectibuprofen-
dc.subjectmetal−organic framework-
dc.titleEncapsulation of Ibuprofen in CD-MOF and Related Bioavailability Studies-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1021/acs.molpharmaceut.7b00168-
dc.identifier.pmid28355489-
dc.identifier.scopuseid_2-s2.0-85018391806-
dc.identifier.volume14-
dc.identifier.issue5-
dc.identifier.spage1831-
dc.identifier.epage1839-
dc.identifier.eissn1543-8392-
dc.identifier.isiWOS:000400633300048-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats